Free shipping on all orders over $ 500

 About 8 results found for searched term "SD-06" (0.182 seconds)

Cat.No.  Name Target
M7558 SD-06 p38 MAPK
SD-06 is a p38 MAP kinase inhibitor; inhibits p38α with an IC50 value of 170 nM and inhibits LPS-stimulated TNF-release in rats (83% inhibition at 1mg/kg, po). IC50 value: 170 nM Target: p38MAPK
M5748 MSDC-0602 PPAR
Azemiglitazone; MSDC0602
Azemiglitazone (MSDC-0602) is a PPARγ -retained thiazolidindione (TZD) that interacts with mitochondrial pyruvate vector (MPC) and inhibits its activity.
M30982 DPI 201-106 Sodium Channel
SDZ 201106
DPI 201-106 (SDZ 201106) is a cardiotonic agent with a synergistic sarcolemmal and intracellular mechanism of action. DPI 201-106 shows cardioselective modulation of voltage-gated sodium channels (VGSCs) resulting in a positive inotropic effect.
M40989 Azemiglitazone potassium PPAR
MSDC-0602K
Azemiglitazone potassium is a thiazolidinediones that binds to PPARγ with an IC50 value of 18.25 μM. It also modulates the mitochondrial pyruvate carrier (MPC). It can be used in studies related to non-alcoholic steatohepatitis (NASH).
M9924 Risdiplam DNA/RNA Synthesis
RG7916; RO7034067
Risdiplam (also known as RG7916 and RO7034067) is a gene splicing modulator (neuromuscular disease) that distributes into the central nervous system (CNS) and peripheral tissues.
M15044 Recombinant Human SDF-1α/CXCL12 (E. coli) Recombinant Proteins
SDF-1-α; SDF1α; CXCL-12
Stromal cell-derived factor-1 α / CXCL12 (SDF-1α) and SDF-1β are members of the α subfamily of chemokines, lacking the ELR domain. Protein construction: SDF-1α/CXCL12 (Lys22-LYS89), Accession # P48061.
M21429 Recombinant Human SDF-1β/CXCL12 (E. coli) Recombinant Proteins
SDF1β; SDF-1 beta; CXCL-12
Stromal cell-derived factor-1β (SDF-1β), also known as SCYB12, PBSF, and CXCL12, is an 8.3 kDa, heparin-bound member of the CXC(or α) chemokine family that signals via the CXCR4 receptor. Protein Construction: SDF-1β/CXCL12 (Lys22-Met93). Accession # P48061.
M28874 PF-06952229  TGF-β Receptor
PF-06952229 is a potent, selective and orally active TGFbR1 inhibitor. PF-06952229 specifically binds to TGFbR1 and prevents TGFbR1-mediated signal transduction. PF-06952229 is a promising antineoplastic agent for the study solid tumors, especifically metastatic breast cancer.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.